Preliminary analysis of the PLA2R1 methylation degrees of high-risk MDS and AML patients during azacitidine treatment indicated that the response to treatment also correlated with the PLA2R1 methylation degrees, and measuring quantitatively the receptor methylation was considered a useful early indicator for the requirement of follow-up therapy19. The gene discussed is PLA2R1; the disease is myelodysplastic syndrome.